limit exceeded
1. N Engl J Med. 2005 Dec 22353252643-53. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Nathan DM, Cleary PA, Backlund JY, Genuth
Please use this identifier to cite or link to this item httphdl.handle.net19282372
Original Article from The New England Journal of Medicine Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes.
IMAGINE WE FOUND THE CURE FOR HEART DISEASE OR DIABETES, but as a society chose to withhold that treatment from those who need it most. Would it be ethical to withhold effective treatments when the result is unnecessary suffering and death that . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 36217 1575-1585. v The NAVIGATOR Study Group. 2010. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Almost all treatment guidelines for patients with diabetes suggest aggressively treating high low-density lipoprotein LDL or "bad" cholesterol and blood pressure levels to reduce patients' risk of developing heart disease, "These recommendations, which are based on the average results of trials evaluating the relative benefits of intensive risk factor control, are not tailored to an individual's underlying cardiovascular disease risk," the authors write.
We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. UK Prospective Diabetes Study UKPDS Group . . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33.
Lifestyle intervention is often more effective in reducing cardiovascular disease, hypertension, heart failure, stroke, cancer, diabetes and all cause mortality than almost any other medical intervention. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus A meta-analysis of randomized controlled trials. Lancet. 3739677 1765-72. Mark Hyman, M.D. is a practicing physician, founder of The UltraWellness